Media About Us


  • 15 July 2016

    Pfizer's Russia Deal Shows Country Still Open To Western Business

    Pfizer's Russia Deal Shows Country Still Open To Western Business

    Kenneth Rapoza / Forbes

    U.S. multinational drug maker Pfizer PFE +1.68% is laying down a new foundation in Russia, with a joint venture announced on Wednesday to produce pharmaceuticals domestically.

  • 15 July 2016

    Pfizer links with NovaMedica to produce and market drugs in Russia

    Pfizer links with NovaMedica to produce and market drugs in Russia

    The Pharma Letter

    US pharma giant Pfizer (NYSE: PFE) and NovaMedica, a company established by Russian high-technology investment fund Rusnano and American venture health care fund Domain Associates in 2012, have entered into an agreement to cooperate, signalling the development of a new partnership, to bring important medicines to the Russian market.

  • 13 July 2016

    Photo: Pfizer and NovaMedica announce a strategic partnership in Russia

    Photo: Pfizer and NovaMedica announce a strategic partnership in Russia

    Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have entered into an agreement to cooperate, signalling the development of a new partnership. Through this partnership, Pfizer proposes to invest in NovaMedica’s construction of a new manufacturing plant in the Kaluga region and license the technology for production of more than 30 medicinal products from its portfolio to the Russian partner.

  • 08 July 2016

    EyewireTV Ц FDA Approves Raindrop Inlay; Humira for Uveitis Treatment

    EyewireTV Ц FDA Approves Raindrop Inlay; Humira for Uveitis Treatment

    EyeWire Today

    In this week’s EyewireTV, ReVision Optics receives FDA approval for the Raindrop Near Vision Inlay, the first implantable device that changes the shape of the cornea to achieve improved vision; and the FDA approves Humira (adalimumab) for the treatment of noninfectious intermediate and posterior uveitis and panuveitis. Also, Bausch + Lomb and Nicox announce that the results of a phase 3 study of glaucoma drug candidate latanoprostene bunod have been published in the American Journal of Ophthalmology.

  • 07 July 2016

    Test Aids Prostate Cancer Treatment

    Test Aids Prostate Cancer Treatment

    Ron Winslow / The Wall Street Journal

    Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival. The test, developed by closely held Epic Sciences Inc., San Diego, detects a mutation associated with a poor response to two new drugs, Xtandi from Medivation Inc. and Astellas Pharma Inc. of Japan, and Zytiga from Johnson & Johnson.

  • 30 June 2016

    New blood test from Epic Sciences matches patients with PARP inhibitors

    New blood test from Epic Sciences matches patients with PARP inhibitors

    Josh Baxt / MedCityNews

    San Diego-based liquid biopsy company Epic Sciences has announced a new blood test that may quickly identify cancer patients who respond to a promising class of drugs called poly ADP ribose polymerase (PARP) inhibitors. The test works by identifying circulating tumor cells (CTCs) affected by homologous recombination deficiency (HRD), a damaged DNA repair mechanism.

  • 28 June 2016

    Epic Sciences unveils new, more sensitive biopsy test to detect a range of cancers

    Epic Sciences unveils new, more sensitive biopsy test to detect a range of cancers

    Joseph Keenan / Fierce Medical Devices

    San Diego's Epic Sciences has added a new liquid biopsy test to its arsenal of biopharma cancer detection tools that targets homologous recombination deficiencies (HRDs) in individual circulating tumor cells.

  • 20 June 2016

    BIO-Europe SpringЃ 2016: RMI says it has USD 200 million already under management

    BIO-Europe SpringЃ 2016: RMI says it has USD 200 million already under management

    EBD Group

    Maxim Gorbachev, a partner and portfolio manager at RusnanoMedInvest (RMI) speaks to Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio about Russia’s and Eastern Europe’s largest venture capital company, specializing in innovative developments in the field of pharmaceuticals and biotechnology. 

  • 09 June 2016

    Treatment for age related loss of near vision: Raindrop near vision inlay one-year clinical results

    Treatment for age related loss of near vision: Raindrop near vision inlay one-year clinical results

    Jeffrey Whitman, MD Key-Whitman Eye Center, Dallas, TX, USA / Atlas of Science

    Presbyopia is an ocular condition associated with age related loss of near vision. The eye loses the ability to focus well on near objects due to the hardening of the natural lens. It affects billions of people worldwide with the onset occurring around age 45. The most common treatment for presbyopia is the use of reading glasses. Recently, surgical correction of presbyopia has been tested as part of a clinical study by implanting a small device into the cornea, the clear front part of the eye.  The Raindrop Near Vision Inlay is an investigational device that is being evaluated to treat this condition so that dependence upon reading glasses may be reduced in order to see objects up close.

  • 13 May 2016

    Good long-term visual acuities reported in presbyopic patients implanted with Raindrop inlay

    Good long-term visual acuities reported in presbyopic patients implanted with Raindrop inlay

    Healio

    Good long-term visual acuities for distance and near were achieved in presbyopic patients, both emmetropic and hyperopic, implanted with the ReVision Optics Raindrop inlay, according to a study presented by Cornelis Verdoorn, MD, at the American Society of Cataract and Refractive Surgery meeting here.